Indices dipped after Johnson & Johnson (JNJ.US) release results of coronavirus vaccine trials. The company said that its one-shot vaccine is 66% effective overall in moderate to severe cases, according to findings of the global clinical trial. Shots were generally well tolerated among trial participants. This is a slightly disappointing result given that some available vaccines have prevented virus infections in over 90% of cases. However, the vaccine is said to be 85% effective in preventing severe cases. Company plans to file for the emergency use approval in the United States in early February.
DE30 dropped around 1% following lacklustre results of Johnson&Johnson coronavirus vaccine trials. Source: xStation5
Morning Wrap: The weekend slump in oil prices is accelerating ๐ฅ (27.07.2026)
Daily Summary: Equities Diverge as Tech Lags, Europe Rallies on Earnings & PMIs (24.07.2026)
Three markets to watch next week (24.07.2026)
US OPEN: Nasdaq hits 1-month low! Geopolitics bring AI trade down!